866-997-4948(US-Canada Toll Free)

PharmSource - Market Opportunities for Contract Manufacturers in Antibody Drug Conjugates

Published By :

GlobalData

Published Date : Jan 2016

Category :

Pharmaceutical

No. of Pages : N/A

PharmSource - Market Opportunities for Contract Manufacturers in Antibody Drug Conjugates

Summary

PharmSources trend report, ADC Market Opportunity for CMOs, is an indispensable resource for understanding the technical developments in the Antibody Drug Conjugate (ADC) sector and the scale of the commercial opportunities and risks for contract manufacturing organizations (CMOs).

The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company has demonstrated proficiency across all four elements of the ADC supply chain: large molecule manufacture, drug conjugation, the toxic payload, and fill/ finish of the conjugate.

Scope

- The prospects for contract manufacturers already involved in or anticipating entry into the sector may be viewed in light of the mixed commercial success of the two approved ADCs, both of which are outsourced.

Reasons to buy

- This 21-page report explores whether the opportunity for ADCs is living up to the bio/pharma industrys enthusiastic expectations and whether CDMOs are making appropriate investments in the technology to support market developments. In particular this trend report seeks to achieve the following objectives -
- To describe and evaluate the ADC market opportunity
- To describe and address the adequacy of the network of CMOs that address the ADC market
- To assess the medium-term outlook for buyers and sellers of contract services for ADCs, including the supply/demand balance.
Table of Contents
Executive Summary 1
Introduction to ADCs 2
Commercial ADC Product Experience 4
ADC Pipeline 5
Next Generation Technologies 7
Approvals Outlook 8
ADC Supply Chain 9
Demand Models 15
What it Means 18
Appendix 20

List of Tables
Table 1 CMOs with Cytotoxic API Manufacturing Capability
Table 2 CMOs Offering Conjugation Services
Table 3 CMOs Entering Conjugation Services Market
Table 4 ADC-Capable Fill/Finish Service Providers
Table 5 Model for ADC Clinical Requirements
Table 6 Model for ADC Commercial Requirements

List of Figures
Figure 1 Schematic of Antibody Drug Conjugate
Figure 2 Industry-Funded Phase 1 Clinical Trials of ADCs
Figure 3 Industry-Funded Phase 2 Clinical Trials of ADCs

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *